These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 26724654

  • 41. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
    J Clin Oncol; 2013 Oct 01; 31(28):3517-24. PubMed ID: 23980084
    [Abstract] [Full Text] [Related]

  • 42. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
    Nault JC, Pigneur F, Nelson AC, Costentin C, Tselikas L, Katsahian S, Diao G, Laurent A, Mallat A, Duvoux C, Luciani A, Decaens T.
    Dig Liver Dis; 2015 Oct 01; 47(10):869-76. PubMed ID: 26211871
    [Abstract] [Full Text] [Related]

  • 43. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS.
    World J Gastroenterol; 2018 Jan 28; 24(4):484-493. PubMed ID: 29398869
    [Abstract] [Full Text] [Related]

  • 44. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction.
    Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR.
    J Magn Reson Imaging; 2014 Nov 28; 40(5):1103-11. PubMed ID: 24214827
    [Abstract] [Full Text] [Related]

  • 45. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E.
    Clin Cancer Res; 2011 Jul 01; 17(13):4504-12. PubMed ID: 21531821
    [Abstract] [Full Text] [Related]

  • 46. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
    Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T, Kurume Liver Cancer Study Group Of Japan.
    Oncotarget; 2016 Sep 27; 7(39):64400-64409. PubMed ID: 27462865
    [Abstract] [Full Text] [Related]

  • 47. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, Imai Y.
    Liver Int; 2013 Apr 27; 33(4):605-15. PubMed ID: 23305331
    [Abstract] [Full Text] [Related]

  • 48. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
    Nakamura Y, Kawaoka T, Higaki T, Fukumoto W, Honda Y, Iida M, Fujioka C, Kiguchi M, Aikata H, Chayama K, Awai K.
    Eur J Radiol; 2018 Jan 27; 98():41-49. PubMed ID: 29279169
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.
    BMC Cancer; 2015 Apr 08; 15():236. PubMed ID: 25885683
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS.
    Oncotarget; 2017 Jul 18; 8(29):47555-47564. PubMed ID: 28548930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.